Neuronetic announced their participation at the American Academy of Child and Adolescent Psychiatry, AACAP, in Seattle, WA, from October 14th-19th, including an oral presentation at the “Research Pipeline: New Findings on Therapeutics” session featuring data generated utilizing the NeuroStar TMS System. In addition, NeuroStar will exhibit at booth #416, where demonstrations of the device will be given.”We are proud to present the largest sample to date of adolescents and young adults with major depressive disorder, highlighting the truly unmatched benefit NeuroStar TMS can provide to this population with limited approved treatment options,” said Cory Anderson, Senior Vice President of Research & Development and Clinical.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STIM:
- Neuronetics, Greenbrook TMS announce receipt of interim order
- Neuronetics Moves to Acquire Greenbrook in Stock Deal
- Neuronetics Outlines Greenbrook Acquisition Prospects and Risks
- Neuronetics announces HCSC expanded access to TMS for adolescents
- Neuronetics announces additional payors have updates their TMS coverage